Most Common Side Effects of Artesunate
Artesunate, an antimalarial drug, most often causes mild to moderate side effects like dizziness, nausea, vomiting, and headache. These occur in 10-20% of patients in clinical trials and post-marketing reports.[1][2]
How Often Do These Happen?
In a large WHO-reviewed safety database of over 100,000 patients treated for severe malaria, side effects were:
- Dizziness: up to 15%
- Nausea/vomiting: 10-12%
- Headache: 8-10%
- Fever or chills: 5-7% (often hard to distinguish from malaria itself)
Serious reactions like hemolytic anemia or delayed hemolysis appear in under 1%, typically 1-3 weeks after treatment.[3][4]
What Happens with IV vs. Oral Dosing?
Intravenous artesunate, used for severe malaria, links to higher rates of post-treatment hemolysis (7-10% in some studies) compared to oral forms (under 2%). Injection-site pain or phlebitis affects about 5% of IV users. Oral artesunate, often in combination therapies like artemether-lumefantrine, shows fewer injection-related issues but similar GI effects.[2][5]
Serious Risks Patients Worry About
Rare but notable:
- Hemolysis: Red blood cell breakdown, sometimes severe; monitor hemoglobin for 4 weeks post-treatment.[4]
- Allergic reactions: Rash, urticaria, or anaphylaxis in <0.1%.[1]
- Liver enzyme elevation: Transient in 2-5%, resolves without intervention.[3]
No evidence of neurotoxicity or cardiotoxicity at standard doses.[2]
Side Effects in Special Groups
Pregnant women (Category C): Similar profile to adults, with no increased fetal risk in second/third trimesters; first trimester data limited.[6]
Children: Lower incidence of dizziness/nausea; hemolysis risk similar.[3]
No major drug interactions reported beyond those with other antimalarials.[1]
Why Do These Side Effects Occur?
Artesunate generates free radicals to kill malaria parasites, which can mildly affect host red blood cells, explaining hemolysis. GI effects stem from rapid IV administration or bitter taste.[2][4]
[1]: WHO Guidelines for the Treatment of Malaria, 3rd ed.
[2]: CDC Artesunate Safety Summary
[3]: NEJM: Safety of Artesunate in Severe Malaria (2010)
[4]: MMWR: Post-Artesunate Delayed Hemolysis (2015)
[5]: Drugs.com: Artesunate Side Effects
[6]: FDA Label: Artesunate for Injection